X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5090) 5090
Book Review (1269) 1269
Publication (349) 349
Newsletter (78) 78
Book Chapter (33) 33
Magazine Article (28) 28
Newspaper Article (25) 25
Conference Proceeding (18) 18
Book / eBook (16) 16
Reference (6) 6
Government Document (3) 3
Web Resource (3) 3
Dissertation (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4408) 4408
index medicus (4263) 4263
thalidomide (2502) 2502
female (2373) 2373
thalidomide - adverse effects (2329) 2329
male (2205) 2205
middle aged (1752) 1752
thalidomide - therapeutic use (1731) 1731
aged (1582) 1582
multiple myeloma - drug therapy (1454) 1454
oncology (1427) 1427
thalidomide - analogs & derivatives (1408) 1408
hematology (1371) 1371
adult (1337) 1337
thalidomide - administration & dosage (1274) 1274
multiple myeloma (1239) 1239
treatment outcome (1104) 1104
lenalidomide (887) 887
antineoplastic combined chemotherapy protocols - therapeutic use (882) 882
bortezomib (859) 859
therapy (791) 791
care and treatment (636) 636
aged, 80 and over (627) 627
dexamethasone (600) 600
antineoplastic agents - therapeutic use (597) 597
antineoplastic combined chemotherapy protocols - adverse effects (580) 580
chemotherapy (580) 580
stem-cell transplantation (548) 548
cancer (536) 536
abridged index medicus (522) 522
dexamethasone - administration & dosage (512) 512
animals (505) 505
drug therapy (483) 483
antineoplastic agents - adverse effects (445) 445
pharmacology & pharmacy (441) 441
survival (410) 410
medicine & public health (407) 407
pregnancy (407) 407
recurrence (388) 388
multiple myeloma - mortality (377) 377
disease-free survival (364) 364
research (353) 353
angiogenesis inhibitors - therapeutic use (351) 351
transplantation (350) 350
multiple-myeloma (346) 346
immunosuppressive agents - therapeutic use (335) 335
risk factors (333) 333
thalidomide - pharmacology (326) 326
multiple myeloma - therapy (319) 319
multiple myeloma - pathology (317) 317
aids/hiv (313) 313
hematology, oncology and palliative medicine (290) 290
retrospective studies (287) 287
prognosis (283) 283
follow-up studies (280) 280
plus dexamethasone (280) 280
health aspects (275) 275
trial (274) 274
angiogenesis inhibitors - adverse effects (273) 273
medicine, general & internal (273) 273
clinical trials as topic (272) 272
dosage and administration (268) 268
clinical trials (266) 266
dose-response relationship, drug (266) 266
antineoplastic combined chemotherapy protocols - administration & dosage (265) 265
immunosuppressive agents - adverse effects (264) 264
dermatology (263) 263
survival analysis (261) 261
analysis (255) 255
combination (254) 254
angiogenesis (253) 253
melphalan (241) 241
drug administration schedule (240) 240
drug therapy, combination (238) 238
efficacy (236) 236
multiple myeloma - complications (234) 234
abnormalities, drug-induced (232) 232
immunologic factors - therapeutic use (231) 231
remission induction (230) 230
child (228) 228
boronic acids - administration & dosage (227) 227
pyrazines - administration & dosage (227) 227
survival rate (224) 224
adolescent (223) 223
disease progression (221) 221
prednisone (218) 218
stem cells (217) 217
dexamethasone - adverse effects (214) 214
antineoplastic agents - administration & dosage (210) 210
multiple myeloma - diagnosis (207) 207
elderly-patients (204) 204
patients (198) 198
complications and side effects (197) 197
time factors (195) 195
immunology (194) 194
diagnosis (193) 193
necrosis-factor-alpha (191) 191
boronic acids - therapeutic use (188) 188
pyrazines - therapeutic use (188) 188
medical research (187) 187
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (8) 8
Robarts - Stacks (5) 5
Online Resources - Online (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Criminology - Stacks (1) 1
East Asian (Cheng Yu Tung) - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Music - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4812) 4812
German (167) 167
Japanese (68) 68
French (66) 66
Spanish (42) 42
Chinese (24) 24
Swedish (15) 15
Dutch (11) 11
Italian (10) 10
Polish (10) 10
Portuguese (10) 10
Czech (9) 9
Russian (9) 9
Hebrew (6) 6
Danish (5) 5
Finnish (4) 4
Hungarian (4) 4
Norwegian (4) 4
Korean (3) 3
Ukrainian (3) 3
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revista de Chimie, ISSN 0034-7752, 08/2016, Volume 67, Issue 8, pp. 1650 - 1653
Recent years witnessed many changes in the treatment of multiple myeloma due to the development of new therapeutic agents. The choice of initial therapy was... 
Velcade (bortezomib) | Dexamethasone | Myeloma | Biochemical factors | biochemical factors | dexamethasone | PROGNOSIS | CELL TRANSPLANTATION | THALIDOMIDE | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | ENGINEERING, CHEMICAL | myeloma | INHIBITION | THERAPY | IN-VIVO | PROTEASOME | LENALIDOMIDE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 4, pp. 933 - 939
Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism... 
TRIAL | PROPHYLAXIS | THERAPY | PLUS DEXAMETHASONE | VENOUS THROMBOSIS | PREVENTION | THALIDOMIDE | THROMBOEMBOLISM | HEMATOLOGY | CANCER | CHEMOTHERAPY | Pulmonary Embolism - prevention & control | Venous Thrombosis - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Incidence | Thalidomide - analogs & derivatives | Venous Thromboembolism - prevention & control | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Aspirin - adverse effects | Adult | Female | Venous Thrombosis - prevention & control | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Venous Thromboembolism - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Thalidomide - adverse effects | Risk Factors | Anticoagulants - therapeutic use | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Israel - epidemiology | Venous Thrombosis - epidemiology | Venous Thromboembolism - chemically induced | Italy - epidemiology | Pulmonary Embolism - chemically induced | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2010, Volume 116, Issue 5, pp. 679 - 686
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article